CHAI

Chai Discovery is an AI-native drug discovery company focused on transforming biology into an engineering discipline. Founded in 2024 by former leaders from OpenAI and Meta, the company develops advanced foundation models to predict and design molecular structures. Their flagship model, Chai-1, is a multi-modal structural prediction tool that outperforms existing benchmarks, including AlphaFold3, in predicting protein-ligand interactions and multi-mer complexes. By integrating high-performance computing with biological data, Chai Discovery aims to significantly accelerate the development of novel therapeutics across various modalities. The company is headquartered in San Francisco and is backed by significant investment from Thrive Capital and OpenAI.